0000899243-22-005006.txt : 20220207
0000899243-22-005006.hdr.sgml : 20220207
20220207160520
ACCESSION NUMBER: 0000899243-22-005006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220203
FILED AS OF DATE: 20220207
DATE AS OF CHANGE: 20220207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mohsen Paulash
CENTRAL INDEX KEY: 0001834063
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 22597398
MAIL ADDRESS:
STREET 1: C/O YUMANITY THERAPEUTICS, INC.
STREET 2: 40 GUESS STREET SUITE 4410
CITY: BOSTON
STATE: MA
ZIP: 02135
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: YUMANITY THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001445283
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 GUEST STREET
STREET 2: SUITE 4410
CITY: BOSTON
STATE: MA
ZIP: 02135
BUSINESS PHONE: 617-409-5300
MAIL ADDRESS:
STREET 1: 40 GUEST STREET
STREET 2: SUITE 4410
CITY: BOSTON
STATE: MA
ZIP: 02135
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140813
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC
DATE OF NAME CHANGE: 20080916
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-03
0
0001445283
YUMANITY THERAPEUTICS, INC.
YMTX
0001834063
Mohsen Paulash
C/O YUMANITY THERAPEUTICS, INC
40 GUEST STREET, SUITE 4410
BOSTON
MA
02135
0
1
0
0
Chief Business Officer
Common Stock
2022-02-03
4
S
0
1958
1.83
D
59135
D
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 to $1.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
/s/ Marie Epstein, Attorney-in-Fact
2022-02-07